

Chagas Disease (American trypanosomiasis) Drug Development Pipeline Study, H2 2018

https://marketpublishers.com/r/C721CFC49BDEN.html

Date: August 2018

Pages: 70

Price: US\$ 1,200.00 (Single User License)

ID: C721CFC49BDEN

Abstracts

Chagas Disease (American trypanosomiasis) Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Chagas Disease (American trypanosomiasis) pipeline products.

DISEASE OVERVIEW

Chagas disease, also known as American Trypanosomiasis, is one of the catastrophic infectious diseases worldwide. An estimated 0.3 million people die from Chagas disease while 8 million+ people are affected annually. The disease presence is determined through microscopic examination of blood smears.

The parasite Trypanosoma cruzi is responsible for spreading this disease. Triatomine bug spreads this disease while sucking blood of humans or animals. Further, blood transfusion, organ transplantation, congenital transmission can be other factors for acquiring Chagas disease.

Due to the strong potential for treatment options for Chagas disease, 10 companies are intensively working on developing new pipeline products. The products under development include both vaccines and treatment options.

Both leading pharmaceutical companies and medium sized players are actively participating in pre-clinical and clinical studies of Chagas disease. The list of companies includes%li%Bayer AG

Collaborations Pharmaceuticals, Daiichi Sankyo Co Ltd, Eisai Co Ltd, Johnson & Johnson, Kancera AB, Novartis AG, Oblita Therapeutics BVBA, RIKEN, Sanofi, Vyera



Pharmaceuticals.

REPORT DESCRIPTION

The Chagas Disease (American trypanosomiasis) pipeline guide presents complete overview of drugs currently being developed for Chagas Disease (American trypanosomiasis). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Chagas Disease (American trypanosomiasis) pipeline candidate.

Research and Development progress along with latest news related to each of the Chagas Disease (American trypanosomiasis) pipeline candidates is included.

Major companies participating in therapeutic development of Chagas Disease (American trypanosomiasis) are included in this pipeline report. Company wise preclinical and clinical products along with details of drug originator, co-developers/licensors are provided.

Amid strong interest for cure of Chagas Disease (American trypanosomiasis) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Chagas Disease (American trypanosomiasis) clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Chagas Disease (American trypanosomiasis) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE REPORT INCLUDES

Panorama of Chagas Disease (American trypanosomiasis) pipeline markets



including statistics on therapeutic drugs and companies involved

Chagas Disease (American trypanosomiasis) Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Chagas Disease (American trypanosomiasis) pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Chagas Disease (American trypanosomiasis) pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Chagas Disease (American trypanosomiasis) pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire Chagas Disease (American trypanosomiasis) pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Chagas Disease (American trypanosomiasis) pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and



company



Contents

I. KEY FINDINGS

1. Companies Investing in Chagas Disease Pipeline include-

Number of Companies with Chagas Disease projects in pre-clinical Development-

Number of Companies with Chagas Disease projects in Clinical Development-

Chagas Disease Pipeline Companies based in Americas

Chagas Disease Pipeline Companies based in Europe

Chagas Disease Pipeline Companies based in Asia Pacific

Chagas Disease Pipeline Companies based in Rest of the World

2. Pipeline Candidates include-

Chagas Disease Pipeline Agents in pre-clinical/Discovery stage of Development

Chagas Disease Pipeline Agents in Clinical Development stage

Chagas Disease Pipeline Therapeutic Compounds received special status

Mechanism of Action of most pipeline Drugs-

Small molecules among the Chagas Disease Pipeline agents

II. INSIGHTS INTO CHAGAS DISEASE PIPELINE

1. Disease Overview

Introduction to Chagas Disease

Symptoms and Causes of Chagas Disease

Treatment or Prevention Options for Chagas Disease

Other Details

2. Phase wise Pipeline Compounds

Chagas Disease Pipeline- Pre- Clinical/Discovery stage Drugs

Chagas Disease Pipeline- Phase 1 stage Drugs

Chagas Disease Pipeline- Phase 2 stage Drugs

Chagas Disease Pipeline- Phase 3 stage Drugs

Chagas Disease Pipeline- Pre-Registration stage Drugs

- 3. Company wise Chagas Disease Pipeline Compounds
- 4. Chagas Disease Pipeline by Mechanism of Action

III. CHAGAS DISEASE PIPELINE COMPOUND DETAILS

nifurtimox

Pyronaridine

Drug for Chagas Disease



fosravuconazole

infectious disease therapeutics

KAN0441411

GNF6702

D121

MAO-1

Fexinidazole

SAR114137

TRP-012

Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co-Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

- 2. Drug Overview
- 3. Mechanism of Action
- 4. Current Status
- 5. Clinical Trial Details

IV. CHAGAS DISEASE PIPELINE COMPANY BRIEFS

Bayer AG

Collaborations Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Eisai Co Ltd

Johnson & Johnson Ltd

Kancera AB

Novartis AG

Oblita Therapeutics BVBA

Sanofi SA

Vyera Pharmaceuticals AG

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL CHAGAS DISEASE PIPELINE MARKET

VI. APPENDIX



- 1. Publisher's Expertise
- 2. Research Methodology
- 3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability



I would like to order

Product name: Chagas Disease (American trypanosomiasis) Drug Development Pipeline Study, H2 2018

Product link: https://marketpublishers.com/r/C721CFC49BDEN.html

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C721CFC49BDEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970